Company Overview: Eupraxia Pharmaceuticals Inc. (TSX: EPRX) is a Canada-based clinical-stage biotechnology company focused on developing locally delivered, extended-release alternatives to existing pharmaceuticals. The company leverages its proprietary Diffusphere™ technology to provide targeted and controlled drug delivery, with the potential to improve treatment effectiveness while reducing systemic side effects. This Report covers Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendation on this one stock.

Canada Market Round-Up

The S&P/TSX Composite Index ended the previous week on a slightly negative note, declining 0.30% to close at 36,620.23 for the week ended August 21, 2026, moderating its recent upward momentum. Despite the pullback, the broader technical outlook remains bullish, with the index continuing to trade comfortably above both its rising trendline support and 21-day Simple Moving Average (SMA), reinforcing the prevailing uptrend and signalling sustained buying interest on market dips. Momentum remains favourable, with the weekly 14-period Relative Strength Index (RSI) at 72.59, indicating strong underlying momentum, although the elevated reading suggests some potential for near-term consolidation or profit-taking. Looking ahead, immediate resistance is positioned near 37,448.40. A decisive breakout above this level could strengthen bullish sentiment and pave the way for further gains. On the downside, immediate support is placed near 35,979.84, where renewed buying interest could help preserve the prevailing uptrend. However, a sustained break below this support would weaken the technical structure and increase the likelihood of a deeper corrective pullback.

On the macro front, the upcoming major economic events that may impact the Canadian market sentiment include CA GDP m/m, US CB Consumer Confidence and US Unemployment Claims.

Past performance is not a reliable indicator of future performance.